Corporate Governance

Company Information

Biodexa Pharmaceuticals is a clinical stage biopharmaceutical company developing a pipeline of products aimed at primary and metastatic cancers of the brain. The Company’s lead candidate, MTX110, is being studied in aggressive rare/orphan brain cancer indications including recurrent glioblastoma, medulloblastoma and paediatric diffuse midline glioma.

Number of ordinary shares: 361,999,722
Countries of listing: US

Country of incorporation and main country of operation

Biodexa Pharmaceuticals PLC is incorporated in England and Wales. Its main country of operation is in the UK.

Constitutional documents

Proposed New Articles of Association (pdf)
Articles of Association (pdf)
Midatech Pharma Limited – Incorporation Documents (pdf)
Midatech Pharma PLC – Certificate of Re-registration (pdf)
Change of Name Biodexa Pharmaceuticals PLC (pdf)

Securities in issue

Details of the number of shares in issue are available here.

QCA Corporate Governance Code

Biodexa Pharmaceuticals has chosen to adopt the principles of the Quoted Companies Alliance Corporate Governance Code (the “QCA Code”). The QCA Code identifies ten principles to be followed in order for companies to deliver growth in long term shareholder value, encompassing and efficient, effective and dynamic management framework accompanied by good communication to promote confidence and trust.

The sections below set out the ways in which the Group applies the ten principles of the QCA Code in support of the Group’s medium to long-term success and identified areas where Biodexa Pharmaceuticals departs from the QCA Code recommendations, is available here.

This disclosure was last reviewed and updated on 28 March 2023.

Directors responsibilities

Details of Biodexa Pharmaceuticals Board of Directors, including biographical information is available here.

The Board of Directors is responsible to the shareholders for the proper management of the Company. It intends to meet regularly to consider the strategy and direction of the Company, to review scientific, operational and financial performance and to advise on management appointments. All key operational and investment decisions are subject to Board approval. The Company Secretary is responsible for ensuring that the Board procedures are followed and applicable rules and regulations are complied with.

Board committees

The Board has three Committees, Audit, Remuneration and Nominations.

The Audit Committee comprises Simon Turton (Chair), Sijmen de Vries and Stephen Parker, and will meet formally not less than twice every year and otherwise as required. The terms of reference of the Audit Committee can be found here.

The Remuneration Committee comprises Sijmen de Vries (Chair), Stephen Parker and Simon Turton and will meet not less than twice a year and at such other times as the chairman of the committee shall require. The terms of reference of the Remuneration Committee can be found here.

The Nominations Committee comprises the full Board and is chaired by Stephen Parker. The Nominations Committee will meet not less than once a year and at such other times as the chairman of the committee shall require. The terms of reference of the Nominations Committee can be found here.

Annual reports, interim reports and RNS

Copies of the Company’s annual reports and interim financial statements may be accessed here.

Circulars

Circulars sent to shareholders are available here.

Takeover code

The City Code on Takeovers and Mergers published by the Panel on Takeovers and Mergers applies to the Company.

Advisers

Details of the Company’s nominated adviser and other key advisers may be found here.

This information was last updated on 11 May 2023.

Leadership

Core to Biodexa Pharmaceuticals strength is its highly experienced and dedicated team.

The Biodexa Pharmaceuticals team benefits from cross-functional expertise including formulation science and pharmaceutical development. With over 10 years’ experience of working together the team has translated multiple programmes from concept to clinic across three distinct technology platforms and apply extensive knowledge and expertise to deliver rapid R&D innovation and value creation.

Stephen Stamp

CEO / CFO

Dmitry Zamoryakhin

Chief Scientific Officer

Dan Palmer

VP Technology

Fiona Sharp

Group Financial Controller

Steve Ellul

VP Business Development

Vincent Holmes

VP Head of Clinical Operations

Board of Directors

Stephen Parker

Non-executive Chairman

Stephen Stamp

CEO / CFO

Simon Turton

Senior Independent Non-executive Director

Sijmen de Vries

Non-executive Director

Annual General Meetings & Notices

Stephen Stamp

CEO / CFO

Mr. Stamp is an experienced public company CFO and has held senior positions in a number of significant healthcare companies including as Group Finance Director of Shire plc, Chief Operating Officer of Xanodyne Pharmaceuticals Inc and most recently with AIM quoted Ergomed plc, where he served initially as CFO before becoming CEO. Mr Stamp qualified as a Chartered Accountant at KPMG and is a member of the Institute of Chartered Accountants.

Dmitry Zamoryakhin

Chief Scientific Officer

Dmitry has joined the company in 2021 as a Chief Scientific Officer and is responsible for all R&D activities of Midatech Pharma. He is a medically trained professional with over 17 years of experience in drug and medical devices development. Prior to joining Midatech Pharma, Dmitry served as a Chief Medical Officer at Oxford Biomedica plc, a company specialising in development products within the cell & gene area. He has also had roles of increasing responsibilities within GSK, Ono Pharma, Daiichi Sankyo and Grunenthal. Dmitry holds a MD from the Perm State Medical Academy (Russia), a MBA from the Warwick University and a diploma in pharmaceutical medicine from the Universite Libre de Bruxelles.

Dan Palmer

VP Technology

Dan has 17 years experience in the biotech sector with particular focus on drug delivery and nanotechnologies for oncology. He has managed interdisciplinary R&D programmes across biology, chemistry and engineering. As well as leading Midatech Pharma’s exploratory oncology R&D, Dan is responsible for management of Midatech Pharma’s intellectual property portfolio. Dan holds a PhD in Chemistry, an MBA from Imperial College Business School and is a Fellow of the Royal Society of Chemistry.

Fiona Sharp

Group Financial Controller

Fiona is a qualified accountant and has held senior finance positions within the PR and advertising industry, including Group Finance Director of Chime Communications Group. Fiona is a Fellow of the Chartered Association of Certified Accountants.

Steve Ellul

VP Business Development

A chemist by training, Steve has spent more than 30 years in commercially focused roles across multiple sectors of the pharmaceutical industry. Steve has led commercial teams at drug delivery organisations, including Eurand and Bespak, and has held senior roles at speciality pharma companies, Elan, Shire and Theravance Biopharma.

Vincent Holmes

VP Head of Clinical Operations

Vincent has over 17 years of experience within the biotech and CRO industries with a keen interest in Oncology and novel therapeutics. He has a breadth of knowledge within Clinical Operations having worked in various roles and sizes of organisation throughout his career, including Quality Assurance. He started his career at large pharma, before moving into the CRO industry and taking a very traditional Clinical Operations career route of Clinical Research Associate and into Project Management. Before joining Midatech Pharma Vince held the position of Vice President, Clinical Operations at the ReNeuron Ltd, where he oversaw Clinical Operations activities of their pipeline.

Simon Parker

Non Executive Chairman

Stephen Parker has over 30 years’ experience in leadership roles both in the healthcare industry and in advisory roles. Currently, he is Chairman of Sareum Holdings plc (AIM: SAR) and Drishti Discoveries Ltd., a Non-Executive Director of MGC Pharmaceuticals Ltd (ASX,LSE: MXC) and an Executive Director of sp2 Consulting Limited. Previously, Stephen held a number of executive and board positions at various public and private biotech companies and senior roles at leading investment banks. Stephen has an MBA from City University and a D.Phil. in biochemistry from Oxford University.

Simon Turton

Senior Independent Non-executive Director

Dr Turton previously headed Warburg Pincus’ healthcare investing activities in Europe and was a principal at Index Ventures in Geneva. He has over 10 years of experience investing in biopharma companies following a ten-year career in the international pharmaceutical industry incorporating roles in research, business development and general management. Dr Turton has an MBA from INSEAD and a Ph.D. in pharmacy from the University of London. He has been a board director of private and public biomedical companies: Archimedes Pharma, Eurand, ProStrakan and Tornier. Dr Turton was most recently chairman of Q Chip prior to its acquisition by the Group. He is currently CEO of Gensmile, a new dental corporate building a group of dental clinics in the UK.

Sijmen de Vries

Non-executive Director

Dr de Vries has extensive senior level experience in both the pharmaceutical and biotechnology industry. He is currently CEO and CFO of Pharming group N.V., the Euronext-listed pharmaceutical company. Dr de Vries was previously CEO of both Switzerland-based 4-Antibody and Morphochem AG, and prior to this he worked at Novartis Pharma, Novartis Ophthalmics and at SmithKline Beecham Pharmaceuticals Plc, where he held senior business and commercial positions. Dr de Vries holds an MD degree from the University of Amsterdam and a MBA in General Management from Ashridge Management College (UK).